In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy
Current therapies against hepatitis B virus (HBV) do not reliably cure chronic infection, necessitating new therapeutic approaches. The T cell response can clear HBV during acute infection, and the adoptive transfer of antiviral T cells during bone marrow transplantation can cure patients of chronic...
Main Authors: | Robert L. Kruse, Thomas Shum, Xavier Legras, Mercedes Barzi, Frank P. Pankowicz, Stephen Gottschalk, Karl-Dimiter Bissig |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-12-01
|
Series: | Molecular Therapy: Methods & Clinical Development |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2329050117300955 |
Similar Items
-
HBV感染者HBsAg和抗-HBs双阳性发生机制
by: REN Meixin
Published: (2014-04-01) -
Clinical features of HBsAg-negative HBV-related hepatocellular carcinoma
by: MA Yan, et al.
Published: (2017-04-01) -
HBsAg loss with HBsAg/anti-HBs seroconversion and non-detectable HCV-RNA in a patient with chronic HBV e-minus/HCV hepatitis treated with two cycles of antiviral therapy
by: Antonio Salvio, et al.
Published: (2012-01-01) -
PROPORTION OF HBsAg AND HBeAg POSITIVE IN MATERNAL PATIENTS AND THEIR HBsAg POSITIVES BABIES WITH IMMUNOPROPHYLAXIS OF HBV IMMUNIZATION IN Dr. SOETOMO GENERAL HOSPITAL, SURABAYA
by: Melina Rosita Tanadi, et al.
Published: (2017-08-01) -
The prevalence of HBsAg and Anti-HCV in pregnant women in Adıyaman
by: Servet Kölgelier, et al.
Published: (2009-01-01)